rs641738C>T near *MBOAT7* promotes steatosis, NASH, fibrosis and hepatocellular carcinoma in non-alcoholic fatty liver disease: a meta-analysis

Kevin Teo[1], Kushala W. M. Abeysekera[2], Leon Adams[3,4], Elmar Aigner[5], Rajarshi Banerjee[6], Priyadarshi Basu[7], Thomas Berg[8], Pallav Bhatnagar[9], Stephan Buch[10], Ali Canbay[11], Sonia Caprio[12], Ankita Chatterjee[7], Yii-Der Ida Chen[13], Abhijit Chowdhury[14], Christian Datz[15], Dana de Gracia Hahn[1], Johanna K. DiStefano[16], Jiawen Dong[1], Amedine Duret[1], EU-PNAFLD Investigators*, Connor Emdin[17], Madison Fairey[1], Glenn S Gerhard[18], GOLD Consortium*, Xiuqing Guo[13], Jochen Hampe[10], Matthew Hickman[2], Lena Heintz19, Christian Hudert[20], Harriet Hunter[1], Matt Kelly[5], Julia Kozlitina[21], Marcin Krawczyk[19,22], Frank Lammert[19], Claudia Langenberg[23], Joel Lavine[24], Lin Li[25], Hong Kai Lim[1], Panu Luukkonen[26,27,28], Phillip E. Melton[29,30], Trevor A. Mori[3], Constantinos A. Parisinos[31], Sreekumar G Pillai[9], Faiza Qayyum[32], Matthias C. Reichert[19], Stefano Romeo[33,34,35], Jerome Rotter[13], Yu Ri Im[1], Nicola Santoro[12], Clemens Schafmayer[36], Elizabeth K. Speliotes[37,38], Stefan Stender[32], Felix Stickel[39], Christopher D. Still[40], Pavel Strnad[41], Kent D. Taylor[13], Anne Tybjærg-Hansen[32], Giuseppina Rosaria Umano[12,42], Mrudula Utukuri[1], Luca Valenti[43,44], Nicholas J. Wareham[23], Julia Wattacheril[45], Hannele Yki-Järvinen[26,27], Jake P. Mann[23]

Affiliations

1. Clinical School of Medicine, University of Cambridge, Cambridge, UK
2. MRC Integrative Epidemiology Unit (IEU), University of Bristol, Bristol, United Kingdom

3. Medical School, Faculty of Medical and Health Sciences, University of Western Australia, Perth, Australia
4. Department of Hepatology, Sir Charles Gairdner Hospital, Perth, WA, Australia
5. Department of Internal Medicine I, Paracelsus Medical University, Salzburg, Austria
6. Perspectum Diagnostics Ltd., Oxford, UK.
7. National Institute of Biomedical Genomics, Kalyani, India
8. Devision of Hepatolgy, Clinic and Polyclinic for Gastroenterology, Hepatology, Infectiology and Pneumology, University Clinic Leipzig
9. Eli Lilly and Company, Indianapolis IN.
10. Medical Department 1, University Hospital Dresden, Technische Universität Dresden (TU Dresden), Dresden, Germany
11. Gastroenterology, Hepatology and Infectiology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
12. Yale University, Department of Pediatrics, New Haven, CT
13. Translational Genomics and Population Sciences Lundquist Institute; Harbor-UCLA Medical Center
14. Institute of Post Graduate Medical Education And Research, Kolkata, India
15. Department of Internal Medicine, General Hospital Oberndorf, Teaching Hospital of the Paracelsus Medical University Salzburg, Oberndorf, Austria
16. Diabetes and Fibrotic Disease Unit Translational Genomics Research Institute (TGen)
17. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Boston, MA
18. Department of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
19. Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany
20. Center for Chronically Sick Children, Charité - Universitätsmedizin Berlin, Berlin, Germany
21. Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX, USA
22. Laboratory of Metabolic Liver Diseases, Department of General, Transplant and Liver Surgery, Laboratory of Metabolic Liver Diseases, Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland
23. MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, UK.
24. Department of Pediatrics, Columbia University, New York, USA
25. BioStat Solutions Inc, Frederick, Maryland, USA
26. Minerva Foundation Institute for Medical Research, Helsinki, Finland.
27. Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
28. Yale University School of Medicine, New Haven, Connecticut, US.
29. The Curtin UWA Centre for Genetic Origins of Health and Disease, Faculty of Health and Medical Sciences, Curtin University, The University of Western Australia, Perth, WA, Australia
30. School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin University, Perth, WA, Australia
31. Institute of Health Informatics, Faculty of Population Health Sciences, University College London, London, UK
32. Department of Clinical Biochemisty, Rigshospitalet Copenhagen University Hospital Copenhagen, Denmark
33. Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden
34. Cardiology Department, Sahlgrenska University Hospital, Gothenburg, Sweden
35. Clinical Nutrition Unit, Department of Medical and Surgical Sciences, University Magna Graecia, Catanzaro, Italy
36. Department of Visceral and Thoracic Surgery, Kiel University, Kiel, Germany Thomas Berg: Department of Internal Medicine, University Hospital Leipzig, Leipzig, Germany
37. Division of Gastroenterology and Hepatology, Department of Medicine, University of Michigan Health System Ann Arbor MI.
38. Department of Computational Medicine and Bioinformatics, University of Michigan Medical School Ann Arbor MI.

39. Department of Gastroenterology and Hepatology, University Hospital of Zurich, Switzerland
40. Geisinger Obesity Institute, Danville, PA 17822, United States
41. Medical Clinic III, University Hospital RWTH Aachen, Aachen, Germany
42. Department of the Woman, the Child, of General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples Italy
43. Department of Pathophysiology and Transplantation, Università degli Studi di Milano
44. Translational Medicine, Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy
45. Department of Medicine, Center for Liver Disease and Transplantation, Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital, New York, New York 10032, USA

*A list of contributors is included in the Acknowledgements

Keywords: *MBOAT7*, fibrosis, NAFLD, triglyceride, diabetes, ALSPAC

Footnote page

Contact information: Dr Jake P. Mann, University of Cambridge, Department of Paediatrics, Cambridge, United Kingdom. jm2032@cam.ac.uk, T: +44 1223 763480, F: +44 1223 336996

Abbreviations (in order of appearance):
NAFLD, non-alcoholic fatty liver disease; NAFL; non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; BMI, body mass index; ALT, alanine aminotransferase; CI, confidence interval; GGT, gamma-glutamyl transferase; OR, odds ratio; *PNPLA3*, patatin-like phospholipase domain containing protein 3; *TM6SF2*, transmembrane 6 superfamily member 2; *TMC4*, transmembrane channel-like 4; *MBOAT7*, membrane bound O-acyltransferase domain containing 7.

Financial support: JPM is supported by a Wellcome Trust Fellowship (216329/Z/19/Z) and a Children's Liver Disease Foundation grant. NIH grants: R01HD028016 (SC), R01DK111038 (SC), R01DK114504 (NS), DK091601 (JKD), UL1TR001105 (JK). This study was supported by the German Federal Ministry for Education and Research (BmBF) through the Livers Systems Medicine (LiSyM) project. This work was supported by grants from the Swiss National Funds (SNF no. 310030_169196) and the Swiss Foundation for Alcohol Research (SSA) to FS. This Raine Study was supported by the National Health and Medical Research Council of Australia [grant numbers 403981, 353514 and 572613]. The UK Medical Research Council and

Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. ALSPAC GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf); This research was specifically funded by grants from MRC and Alcohol Research UK (MR/L022206/1) and NIH (5R01AA018333-05) to KWMA & MH. LV was supported by MyFirst Grant AIRC n.16888, Ricerca Finalizzata Ministero della Salute RF-2016-02364358, Ricerca corrente Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, LV and AG. received funding from the European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377) for the project LITMUS-" Liver Investigation: Testing Marker Utility in Steatohepatitis". German Federal Ministry of Education and Research (BMBF LiSyM 031L0051 to F.L.) PL is supported by grants from the Sigrid Jusélius Foundation and the Novo Nordisk Foundation. The Fenland study was funded by grants to the MRC Epidemiology Unit (MC UU12015/1, MC UU 12015/5). RB and MK are employees of and shareholders in Perspectum Diagnostics Ltd. CAP is funded by a Wellcome Trust Clinical PhD Programme (206274/Z/17/Z).

ABSTRACT

A common genetic variant near *MBOAT7* (rs641738C>T) has been previously associated with hepatic fat and advanced histology in non-alcoholic fatty liver

disease (NAFLD), however, these findings have not been consistently replicated in the literature. Therefore, we aimed to establish whether rs641738 is a risk factor for NAFLD through meta-analysis. Data from 134,015 participants (7,692 with liver biopsies and 50,680 with imaging) was included in the meta-analysis. The minor T-allele of rs641738C>T was associated with higher liver fat on CT/MRI using an additive genetic model (+0.05 standard deviations [95% CI: 0.01 – 0.09], p=0.025), and with an increased risk of NAFLD (per-allele OR: 1.08 [95% CI: 1.01 - 1.15]), nonalcoholic steatohepatitis (OR: 1.11 [95% CI: 1.02 - 1.21]), advanced fibrosis (OR: 1.14 [95% CI: 1.05 - 1.23]), and hepatocellular carcinoma (OR: 1.43 [95% CI: 1.22 - 1.67]) in adults with NAFLD. Sub-group analysis did not demonstrate a difference in Caucasians and non-Caucasians. Rs641738C>T was not associated with markers of insulin resistance but was associated with higher risk of stroke in the UK Biobank. These data validate rs641738C>T near *MBOAT7* as a risk factor for the development, activity, and stage of NAFLD including hepatocellular carcinoma.

Abstract word count: 192

Conflict of interest: Connor Emdin reports personal fees from Navitor Pharma and Novartis.

179 **INTRODUCTION**

180 Since the first genome-wide association study (GWAS) of liver fat (1), more
181 than 20 genetic single nucleotide variants (SNVs) have been associated with
182 non-alcoholic fatty liver disease (NAFLD)(2). These studies have deepened
183 our understanding of the condition, its heritability, and its relationship with
184 cardio-metabolic disease.

185

186 Rs641738C>T near *MBOAT7* (membrane bound O-acyltransferase domain
187 containing 7) was initially identified as a genome-wide significant risk locus for
188 alcohol-related cirrhosis(3). It has since been implicated in the pathogenesis
189 of NAFLD(4), hepatocellular carcinoma(5), as well as in fibrosis development
190 in chronic hepatitis B and C.

191

192 This SNV is located a few hundred base pairs downstream of the 3'
193 untranslated region of *MBOAT7*, which belongs to a family of genes that code
194 for specific acyl donors and acceptors. *MBOAT7* encodes
195 lysophosphatidylinositol acyltransferase 1 (LPIAT1), which contributes to the
196 regulation of free arachidonic acid in cells(6). Rs641738C>T is associated
197 with lower hepatic expression of *MBOAT7* at both the mRNA(7) and protein
198 level(4). Given its role in inflammatory lipid pathways, most mechanistic work
199 relating to rs641738 has focused on *MBOAT7*.

200

201 In NAFLD, the rs641738 variant was first demonstrated to be associated with
202 increased hepatic fat content and severity of fibrosis in individuals of
203 European descent(4). Proton magnetic resonance spectroscopy data from

2736 individuals showed a modest increase in hepatic fat in those with TT-genotype (4.1%) compared to those with CT- (3.6%) or CC-genotype (3.5%) (p=.005). Follow-up studies of European subjects corroborated the initial findings, and suggested a role in development of hepatocellular carcinoma(8,9). However, these results were not replicated in adults of other genetic ancestries(4,10–12) or in children(13). It is recognised that investigation of candidate genes in relatively small cohorts can generate false-positive findings.

In addition, biallelic loss of function mutations in *MBOAT7* cause autosomal recessive mental retardation 57 (OMIM #617188) and no liver phenotype has been reported in these patients to date(14), however, rare likely pathogenic variants in *MBOAT7* are associated with HCC in NAFLD(15). In summary, the association between rs641738 and hepatic fat content, as well as its effects on severity of NAFLD, remain unclear. Moreover, the broader metabolic effects of this SNV, including its association with diabetes and cardiovascular outcomes, have not been assessed.

Here, we conducted a large meta-analysis of published and unpublished data to determine if rs641738 influences the development or stage of NAFLD and associated cardio-metabolic phenotypes.

225 **PATIENTS AND METHODS**

226

227 **Data sources and study selection**

228 Two data sources were included in the meta-analysis: published studies (and
229 abstracts) and unpublished GWAS (or targeted genotyping) data.

230

231 Published studies were sourced through Medline and Embase using the
232 search terms "(*MBOAT7* or membrane-bound-o-acyltransferase) or (rs641738
233 or rs626283) or (*TMC4*)". There were no restrictions on date or language, and
234 the study selection included all original studies including AASLD Liver Meeting
235 and EASL meeting abstracts. The search was completed on 1st October 2019.
236 Reference lists of relevant publications were also reviewed. Titles and
237 abstracts were screened for eligibility independently by two authors, with
238 inclusion/exclusion criteria applied to potentially eligible full texts.

239

240 A search was conducted for all GWAS in NAFLD, NASH, and steatosis.
241 Authors of all potentially relevant GWAS were contacted to request extraction
242 of data regarding rs641738C>T. To assess for cardiometabolic phenotype
243 associations, Phenoscanner(16) and GeneATLAS(17) were searched for
244 summary statistics from published GWAS.

245

246 HuGENet guidelines were followed throughout. This study was prospectively
247 registered on PROSPERO Database of Systemic Reviews
248 (CRD42018105507) Available from:

http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018105507

Inclusion and exclusion criteria

Cohort and case-control studies related to NAFLD were included if genotyping of rs641738C>T (or other SNVs in linkage disequilibrium [LD, R^2>0.8]) was conducted and data on one of the outcomes of interest were reported. Review articles, *in vitro* studies, and investigations involving animal, fish, and invertebrates were excluded. Studies which investigated liver disease of other etiologies were also excluded.

Data collection

For each study, data on participant demographics (sex, age, ethnicity) were collated. Hepatic steatosis or NAFLD (as diagnosis) was evaluated as a dichotomous variable where radiological assessment (liver ultrasound, controlled attenuation parameter [CAP, with cut-off >240m/s], CT, MRI) were used. Hepatic fat content (from CT, MRS, MRI, PDFF), serum lipid profile, fasting insulin, and alanine aminotransferase levels were collected as continuous variables. Hepatic fat content was also assessed using semi-quantitative scoring in the Fenland cohort, as previously described(18), and using CAP. Histology data were extracted according to the NASH Clinical Research Network scoring system and, where not otherwise diagnosed by a pathologist's assessment, NASH was defined using the Fatty Liver Inhibition of Progression (FLIP) algorithm. The above data were collected for each genotype separately (CC, CT, and TT).

Phenoscanner was used to assess for disease associations with rs641738C>T at P<0.01. Phenotype associations were filtered for those related to cardio-metabolic and liver disease.

The authors of 21 published studies were contacted for additional data, all of whom replied. Several studies reported outcomes from overlapping cohorts: ref (4) and ref (19); ref (9) and ref (20). In these instances, data only from the larger of the overlapping cohorts were included in analyses.

Cohorts with genome-wide data

The authors of 10 potentially relevant GWAS (and cohort studies with genome-wide data) were contacted, of which 9 replied and data were included from 7.. Densely imputed genotyping data were available for rs641738C>T in all with >0.98 call rate. These cohorts have been described elsewhere and detailed description of the quality control processes for genome-wide data is available in their original descriptions(1,21,30,31,22–29), but in brief, single nucleotide polymorphisms (SNP) with Hardy-Weinberg equilibrium p-values $<1x10^{-6}$ were excluded prior to imputation. Imputation was performed for variants with mean allele frequencies >.01 and with minimum imputation quality of >0.3.

Previously unpublished data was included from the Avon Longitudinal Study of Parents and Children (ALSPAC)(30–32). This is a prospective, longitudinal study that originally enrolled 14,541 pregnancies with expected delivery dates between 1st April 1991-31st December 1992. After enrolment of 913 additional

299 children at age 7, the total sample size is 15,454 pregnancies, resulting in
300 15,589 foetuses. Of these 14,901 were alive at 1 year of age. Ethical approval
301 for the study was obtained from the ALSPAC Ethics and Law Committee and
302 the Local Research Ethics Committees. Data included in this meta-analysis
303 was from individuals who had attended a study visit between 22 and 26 years
304 of age for transient elastography measurement with controlled attenuation
305 parameter (CAP). Please note that the ALSPAC study website contains
306 details of all the data that is available through a fully searchable data
307 dictionary and variable search tool
308 (http://www.bristol.ac.uk/alspac/researchers/our-data). Data was included for
309 meta-analysis where a CAP measurement was recorded and the participant
310 had genotyping data for rs641738C>T, which left 2,919 individuals for
311 inclusion.
312 Unpublished data from the UK BioBank was extracted under Application ID
313 9914 ('Determining the Outcomes of People with Liver Disease').
314
315 **Study quality assessment**
316 Two reviewers independently assessed risk of bias in each study by applying
317 the Cochrane Risk of Bias in Cohort Studies tool.
318
319 **Statistical Analysis:**
320 For dichotomous outcomes, the effect statistic was calculated as an odds ratio
321 between groups. Genetic association analyses were performed using an
322 additive model to estimate the effect per T-allele as almost all included studies
323 had used this model.

324 For analysis of effect on liver fat, data were inverse normalized and an
325 additive genetic model (coding the number of T alleles as 0, 1, and 2) was
326 used with linear regression, adjusted for age, sex, and principal components
327 of genetic ancestry (where available). In addition, data from the GOLD
328 Consortium were adjusted for number of alcoholic drinks consumed.
329 Continuous quantitative liver fat data (from CT, MRI, MRS, or PDFF) and
330 semi-quantitative data (ultrasound and CAP) were analyzed separately.
331 For other continuous variables, effect summary was calculated as a mean
332 difference between CC and TT groups.
333 Meta-analysis was performed using random effects throughout.
334 Summary statistics were reported with 95% confidence intervals (CI). Data
335 from paediatric and adult studies were analyzed separately. Sub-analysis was
336 performed using only studies with Caucasian (Non-Finnish or Finnish
337 European ethnicity) where data were available from at least four studies. This
338 sub-analysis was selected due to initial identification of this variant in
339 Caucasian individuals, further sub-analysis by ethnicity may be affected by
340 differences in linkage disequilibrium between genetic ancestries.
341 Leave-one-out sensitivity analysis was performed for all outcomes using
342 additive model of inheritance and random effects.
343 Heterogeneity between groups was described using the Q statistic and I^2.
344 Bias was assessed using Egger's test and visually using funnel plots where
345 more than 5 studies were included. $P < 0.025$ (i.e. $P < 0.05/2$) was considered
346 statistically significant due to testing outcomes twice: in individuals of all
347 ethnicities and Caucasians only. Analysis was performed using STATAv14 for
348 Windows (StataCorp. 2015. Stata Statistical Software: Release 14. College

Station, TX: StataCorp LP), DistillerSR Forest Plot Generator from Evidence Partners (https://evidencepartners.com/resources/forest-plot-generator/), GraphPad Prism (v8.0 for Mac, GraphPad Software, La Jolla California, USA), and MetaGenyo(33).

RESULTS

Database search identified 405 abstracts, of which 18 studies were included. In addition, unpublished data were extracted from 12 cohorts (Table 1, Supplementary Fig. 1, and Supplementary Table 1).

Study Age group	Genetic ancestry (country)	Study design and sample size (N)	Female, n (%)	Features and patient characteristics	Liver biopsy (N)
Published					
Di Sessa, 2018; Paediatric (34)	Non-Finnish European (Italy)	Cases-only Hospital-based N=1002	466 (46.5%)	Children with hepatic steatosis measured by US	NA
Di Costanzo, 2018; Adult (35)	Non-Finnish European (Italy)	Case-control N=445	150 (33.7%)	Hepatic steatosis measured by US	NA
Dongiovanni, 2018b; Adult (36)	Mixed: Non-Finnish European and Finnish European	Cases-only N=1,388 (LBC)	728 (52.4%)	NAFLD diagnosed by LB (LBC)	1515
Lin, 2018; Paediatric (37)	East Asian (China)	Population-based N=831	257 (31.4%)	Hepatic steatosis measured by US	NA
Viitasalo, 2016; Paediatric (38)	Finnish European (Finland)	Population-based N=512	222 (47.5%)	Population cohort of children with measurement of ALT	NA
Koo, 2018; Adult (10)	East Asian (Korea)	Case-control Hospital-based N=525	264 (50.3%)	Adults with NAFLD diagnosed by LB, or US/MRI/CT	416
Published and unpublished data					
Hudert, 2018; Paediatric (13)	Non-Finnish European (Germany)	Case-control Hospital-based N=270	92 (34%)	Patients: children with NAFLD diagnosed by LB Controls: healthy population (adult) controls	70
Mann, 2018a; Adult (24)	Non-Finnish European	Population cohort N=10,934	5,823 (53.2%)	Hepatic steatosis measured by US	NA

	(England)				
Mann, 2018b; Paediatric (39)	Non-Finnish European (Italy)	Hospital-based N=67	34 (50.7%)	Children with NAFLD diagnosed by LB	67
Umano, 2018; Paediatric (12)	Mixed: Non-Finnish European, African American, Hispanic (USA)	Cases-only Hospital-based N=860	509 (59.2%)	Hepatic steatosis measured by MRI	NA
Krawczyk, 2018; Adult (20)	Non-Finnish European (Germany)	Cases-only N=237	24 (38.1%)	Adults with NAFLD diagnosed by LB, or US/MRI/CT	63
Krawczyk, 2017; Adult (9)	Non-Finnish European (Germany)	Cases-only N=515	280 (54.4%)	Adults with NAFLD diagnosed by LB, or US/MRI/CT	320
Kawaguchi, 2018; Adult (25)	East Asian (Japan)	Case-control Mixed hospital- and population-based N=8,608	5111 (59.6%)	Patients: Adults with NAFLD diagnosed by LB Controls: healthy population controls	936
Dongiovanni, 2018; Adult (19)	Mixed: Non-Finnish European, African American, Hispanic (USA)	Population cohort: N= 4,570 (DHS), Cases-only Hospital-based: N=1,515 (LBC)	3,330 (54.7%)	Hepatic steatosis measured by H-MRS (DHS) or NAFLD diagnosed by LB (LBC)	1515

Mancina, 2016; Adult (4)	Mixed: Non-Finnish European, African American, Hispanic (USA)	Population cohort: N= 3,854 (DHS) Cases-only Hospital-based: N=1,149 (LBC)	2754 (54.4%)	Hepatic steatosis measured by H-MRS (DHS) or NAFLD diagnosed by LB (LBC)	1149
Luukkonen, 2016; Adult (8)	Finnish European (Finland)	Cases-control Hospital-based N=125	83 (66.4%)	Adults assessed for NAFLD by LB	125
Donati, 2017; Adult (5)	Non-Finnish European (Italy / UK)	Case-control Hospital-based N=765 (Italian) N=358 (UK NAFLD)	188 (24.6%) 143 (39.4%) 387 (34.5%)	Adults with NAFLD diagnosed by LB	1123
Sookoian, 2018; Adult (11)	Caucasian (Argentina)	Case-control Hospital-based N=634	360 (57.0%)	Patients: adults with NAFLD diagnosed by LB Controls: hepatic steatosis absent on US	372
Unpublished data					
UKBB cohort, 2019; Adult	Non-Finnish European (UK)	Population-based N=7,078	3,822 (54%)	GWAS of hepatic steatosis measured by MRI from the UK BioBank.	NA
DiStefano, 2015; Adult (21)	Non-Finnish European (USA)	Cases-only Hospital-based N=1,868	1,512 (80.9%)	GWAS of adults with NAFLD diagnosed by LB	1868
Adams, 2013; Paediatric (22)	Non-Finnish European (Australia)	Population-based N=928	444 (47.8%)	GWAS of adolescents with hepatic steatosis measured by US	NA

Lauridsen, 2018; Adult (40)	Non-Finnish European (Denmark)	Population-based N=7511	775 (53.9%)	Hepatic steatosis measured by CT, part of the Copenhagen General Population Study	NA
Luukkonen, 2018; Adult (41)	Finnish European (Finland)	Cases-only Hospital-based N= 38	21 (55%)	Hepatic steatosis measured by MRS	NA
Speliotes 2011; Adult (1)	Mixed: Non-Finnish European, African American, Hispanic (USA, Iceland, Europe)	Population-based N=4,244	-	GWAS of hepatic steatosis measured by CT	NA
Strnad, Buch, & Hamesch, 2018; Adult (42,43)	Non-Finnish European (Germany, Austria, & Switzerland)	Case-control Hospital-based N=1184	573 (48.4%)	Adults with NAFLD diagnosed by LB	672
Emdin, 2019; Adult (26)	Non-Finnish European (UK)	Population-based N=77,464	42,144 (54%)	Adults with coded diagnosis of NAFLD and/or cirrhosis	NA
Reichert, 2019; Adult (44)	Non-Finnish European (Germany)	Hospital-based N= 54	24 (42.1%)	Adults with NAFLD cirrhosis diagnosed by LB, or US/MRI/CT	NA
Guzman, 2018; Adult (27)	Mixed: Hispanic and non-Hispanic (USA)	Case-control N=246 (GLDI study)	104 (42.3%) 57	Adults with Type 2 Diabetes with hepatic steatosis measured by MRI	NA

		Case-control N=158 (GLDJ study)	(36.1%)		
Wattacheril, 2017; Paediatric (28)	Hispanic (USA)	Cases-only N=208	0 (all male)	GWAS of Hispanic boys with NAFLD diagnosed by LB	208
Chatterjee, 2018; Adult (29)	South Asian (India)	Hospital-based N=354	138 (38.9%)	GWAS of adults with NAFLD diagnosed by LB or US	132
Abeysekera, 2019 (30,31,45); Adult	Non-Finnish European (UK)	Population-based N=2,919	1,781 (61%)	GWAS data from the ALSPAC birth cohort study with steatosis diagnosed using CAP >280kPa	NA

Table 1. Characteristic of studies included in the meta-analysis. ALSPAC, Avon Longitudinal Study of Parents and Children; CAP, controlled attenuation parameter; CT, computerized tomography; DHS, Dallas Heart Study; GWAS, genome-wide association study; LB, liver biopsy; LBC, Liver Biopsy Cohort; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NA, not applicable; US, ultrasound.

<Table 1.>

In total, 134,015 individuals (4,174 children) were included in the meta-analysis. Most studies were in adults (24/31, 77%) and in individuals of European ancestry (21/31, 68%). Of the 31 included studies, 15 (totaling 7,692 unique participants, hereof 345 children) reported data on liver histology.

Liver fat, NAFLD, and severe steatosis in adults

Seven studies (21,924 participants) reported data on hepatic fat as a continuous variable assayed by CT or MR (1,19,27,29,40). In meta-analysis across these seven studies, rs641738 was associated with increased liver fat, with a per T-allele increase of 0.05 (95% CI 0.01 - 0.09) standard deviations in inverse normalized liver fat (Figure 1). There was significant heterogeneity between studies with I^2 = 67% and Tau^2=.002. This trend of association remained on sub-analysis including only cohorts with Caucasian (European) ethnicity (Supplementary Figure 2).



377 *Figure 1.* ***The effect of rs641738C>T on liver fat.*** *Data from 21,924*
378 *individuals with CT or MRI liver fat. T-allele was associated with a small*
379 *increase in liver fat, where data represents standard deviation change in*
380 *normalized liver fat per T-allele. CGPS, Copenhagen General Population*
381 *Study; CI, confidence interval; ES, effect summary; GOLD, Genetics of Liver*
382 *Disease; N, number of individuals included; UKBB, UK BioBank.*
383
384 The rs641738 variant C>T was also associated with NAFLD as a trait (OR
385 1.08 (95% CI 1.01, 1.15) using an additive model of inheritance (Figure 2A).
386 Sensitivity analysis using the leave-one-out method did not demonstrate any
387 individual study to affect the estimate (Supplementary Figure 3) and there was
388 no evidence of study distribution bias on funnel plot (Egger's test p=0.23,
389 Supplementary Figure 4). The trend of a positive association was seen on
390 sub-analysis in Caucasians (OR 1.10 (95% CI 0.99, 1.21), Supplementary
391 Figure 5A).
392



Figure 2. ***rs641738C>T is associated with higher odds of diagnosis of NAFLD and histological severity of steatosis****. Data from 31,462 adults with radiologically defined steatosis for presence versus absence of NAFLD (2A), and from 4,572 adults with liver biopsy data for presence of severe steatosis (S0-2 versus S3, 2B) using an additive model of inheritance. ALSPAC, Avon Longitudinal Study of Parents and Children; LBC, Liver Biopsy Cohort.*

In patients with NAFLD, rs641738C>T was associated with the presence of severe steatosis (S0-2 vs. S3) on liver biopsy (OR 1.26 [95% CI 1.12, 1.41], Figure 2B). This association remained on sub-analysis in Caucasian individuals (OR 1.28 [95% CI 1.14, 1.45], Supplementary Figure 5B). A similar trend was observed using CAP and semi-quantitative ultrasound to assess

steatosis severity (β .02 (95% CI -.002, .04) standard deviations of inverse normalized liver fat score per T-allele, Supplementary Figure 6).

Histological NASH in adults

Data from 9 studies (6,155 participants) showed that rs641738C>T was positively associated with the presence of NASH on biopsy in adults (OR 1.11 (95% 1.02, 1.21, Figure 3). A similar magnitude of effect was observed on sub-analysis in Caucasian individuals (OR 1.13 (95% 1.01, 1.27, Supplementary Figure 7).



Figure 3. ***rs641738C>T is associated with higher odds of NASH on biopsy****. Data from 6,155 adults with NASH defined according to the FLIP algorithm for NAFL versus NASH, using an additive model of inheritance. NAFL, non-alcoholic fatty liver.*

Fibrosis in adults

426 Data from 8 studies (82,857 adults, 6,787 with liver biopsy data) were
427 included in meta-analysis of fibrosis. Our primary outcome, presence of
428 advanced fibrosis in adults (stage F0-2 versus stage F3-4), was positively
429 associated with T-allele (OR 1.14 (95% 1.05, 1.23), Figure 4A) in adults.
430 Sensitivity analysis, including omission of coded cirrhosis data from Emdin *et*
431 *al.*(26), did not alter the effect summary (Supplementary figure 8). Presence of
432 any fibrosis (stage 0 versus stage 1-4) was also positively associated with
433 rs641738C>T (OR 1.14 (95% 1.01, 1.28), Figure 4B). On sub-analysis of
434 Caucasian individuals, rs641738C>T was associated with advanced fibrosis
435 (OR 1.16 (95% 1.06, 1.26)) but not with any fibrosis (OR 1.15 (95% 0.99,
436 1.34)) despite a positive trend (Supplementary figure 9).
437



438

439 *Figure 4.* ***rs641738C>T is associated with increased fibrosis in NAFLD****. A,*
440 *data from 6,787 adults with biopsy-proven NAFLD (plus coding data from*

441 *Emdin et al.) comparing advanced fibrosis (F3-4) versus F0-2, using an*

442 *additive model of inheritance. B, data from 6,787 adults with biopsy-proven*

443 *NAFLD comparing any fibrosis (F1-4) versus no fibrosis F0.*

444

445 **Development of hepatocellular carcinoma**

446 Five cohorts (3,803 participants, 360 cases of NAFLD-HCC) reported on

447 development of HCC in patients with NAFLD. Presence of T-allele was

448 associated with increased odds of HCC in NAFLD (OR 1.43 (95% CI 1.22,

449 1.67, Figure 5).

450



451

452 *Figure 5.* ***rs641738C>T is associated with higher odds of NAFLD-HCC****.*

453 *Data from 3,803 adults with NAFLD assessing for the presence versus*

454 *absence of HCC, using an additive model of inheritance.*

455

456

457 **Effect on aminotransferases, lipids, and fasting insulin**

458 Data from 12 studies (17,148 participants) was available for meta-analysis of

459 serum biochemical parameters. T-allele was associated with lower

460 triglycerides (mean difference CC versus TT genotype -3.7 mg/dL (95% CI -

461 7.2, -0.2)) but no other effect on aminotransferases, serum lipids, or fasting

462 insulin (Table 2).

463

	Number of cohorts	P_Q	I^2	Random effects		
				Mean difference	[95% CI]	P_z
ALT, IU/L (n=17,102)	14	.44	.01	-.27	-.91, 0.37	.41
Triglycerides, mg/dL (n=17,148)	15	.19	.23	-3.71	-7.22, -.20	.04
Total cholesterol, mg/dL (n=16,822)	13	.009	.52	.45	-2.41, 3.31	.76
High-density lipoprotein, mg/dL (n=9,843)	10	.08	.39	-.26	-1.31, .80	.63
Low density lipoprotein, mg/dL (n=8,800)	7	.18	.30	2.06	-.30, 4.42	.09
Fasting insulin, mU/L (n=6,269)	4	.004	.71	-.66	-2.52, 1.20	.49

464

465 *Table 2. Meta-analysis for the effect of rs641738C>T on biochemical indices liver*
466 *damage dyslipidemia, and insulin resistance. Data represents the mean difference*
467 *between CC and TT genotypes using random effects. N represents the sum of*
468 *individuals with CC and TT genotypes included in each analysis.*

469

470

471

472 **Disease outcomes in adults**

473 Using data from previous meta-analyses via Phenoscanner and UK BioBank

474 data via GeneAtlas, rs641738C>T was weakly positively associated stroke (β

475 0.0007, p=0.004), Supplementary table 2). There was no evidence of an

476 association with type 2 diabetes, coronary artery disease, or chronic kidney

477 disease. It was also associated with higher alkaline phosphatase (β 0.005,

478 $p=6.1x10^{-6}$).

479

480 **Effect of rs641738C>T on paediatric NAFLD**

Data from seven studies (4,174 children) was used in the meta-analysis. rs641738C>T was not significantly associated with any disease outcome studied (Supplementary table 3 and Supplementary Figure 10). However there was a trend towards increasing hepatic fat fraction (0.19 SD (95% CI -0.05, 0.42)) and severity of steatosis (OR 1.21 (95% 0.89, 1.64)).

492 **DISCUSSION**

493 Identification of genetic variants associated with NAFLD has the potential to
494 inform pre-clinical research and our understanding of hepatic metabolism. In
495 this meta-analysis we have validated the importance of rs641738C>T near
496 *MBOAT7* on the full spectrum of NAFLD in adults.

497

498 A two-stage GWAS initially identified rs641738C>T as a genome-wide
499 significant locus for alcohol-related cirrhosis(3). *MBOAT7* was a potentially
500 interesting target as an enzyme involved in (phosphor)lipid metabolism,
501 conceptually similar to other SNVs at GWAS-significance in alcoholic and
502 non-alcoholic liver disease, namely *TM6SF2* and *PNPLA3*. Later studies
503 found the variant to influence the full spectrum of fatty liver disease, from
504 steatosis to NASH, to fibrosis, cirrhosis and HCC(4,8). However, these
505 associations have not been consistently replicated in the literature(11). We
506 conducted a meta-analysis to firmly establish the association of rs641738C>T
507 with NAFLD.

508

509 **Main findings**

510 We found that the T-allele of rs641738C>T was associated with higher liver
511 fat content, and with an increased risk of NASH, fibrosis, and HCC. The
512 effects sizes of rs641738C>T reported here are small compared to those of
513 PNPLA3 p.I148M and TM6SF2 p.E167K, the two strongest steatogenic
514 variants(2). Also, unlike NASH-associated variants in *PNPLA3*, *HSD17B13*,
515 *MARC1*, and *TM6SF2*, there was no association between this *MBOAT7*
516 variant and alanine or aspartate aminotransferase. The marginal positive

effect of this variant on hepatic triglyceride content may suggest alterations in the composition of hepatic lipid, rather than quantity(8). This is consistent with pre-clinical data on lipotoxicity, where the composition of hepatic fats influence development of NASH. On the other hand, a recent Mendelian randomization study using these variables as instruments to assess causality of fatty liver in determining fibrosis has shown the effect of steatosis highly correlates with fibrosis in all the genetic variables indicating that quantity of lipid rather than quality may be more important(19). Functional studies are needed to understand the relationship between quality/quantity of fat and hepato-toxic/-protective mechanism in causing progression of disease.

The function of this variant is still relatively poorly understood and there is conflicting evidence as to whether rs641738 is associated with changes in hepatic expression of *MBOAT7*. Results from the GTEx Consortium show a strong negative association with T-allele(7), which is supported by data from Schadt et al.(46). *MBOAT7* protein expression correlated with mRNA in liver biopsies from Mancina *et al.*(4) but this finding was not replicated by Sookoian *et al.*(11). *MBOAT7* encodes LPIAT1, a 6 transmembrane domain protein involved in acyl-chain remodeling of membranes that influence intracellular membrane composition and circulating phosphatidylinositols(8). Further recent metabolite profiling data implicates *MBOAT7* as the causal gene for this SNV(24). Moreover, TMC4 was found with a low expression in the liver(4) that is consistent with no mechanistic data supporting its role in NAFLD.

541 The hypothesis that *MBOAT7* is the causal gene underlying the association
542 with liver disease at the locus is supported by the observation that mice
543 deficient for *MBOAT7* have altered hepatic concentrations of polyunsaturated
544 phosphatidylinositol(47). Similarly, metabolite data from humans is strongly
545 suggestive that rs641738C>T reduces MBOAT7 function(48). In addition, loss
546 of *MBOAT7*, but not TMC4, increases the severity of NAFLD in mice fed a
547 high-fat diet(49). It is not known whether these genetically modified animals
548 have increased susceptibility to HCC.
549
550 This variant shows a particularly strong association with development of HCC.
551 It is unclear whether this reflects the effect on NASH-fibrosis or if there is a
552 specific causal relationship between *MBOAT7* and HCC.
553
554 We found no evidence of rs641738 on insulin resistance: the key driver of
555 hepatic steatosis, as determined by unaltered fasting insulin concentrations.
556 GWAS meta-analyses of type 2 diabetes have implicated p.I148M in PNPLA3
557 and p.E167K in TM6SF2 as significant risk loci (albeit with very modest effect
558 size as compared to their effects on liver disease) and a Mendelian
559 randomization study indicates a causal role in determining insulin resistance
560 mediated by the degree of liver damage(19). Similarly, these two variants are
561 associated with reduced risk of coronary artery disease whereas rs641738
562 has no effect. It does, however, appear to be weakly associated with higher
563 prevalence of stroke in the UK BioBank(17). Our analysis also found lower
564 serum triglycerides in those with TT-genotype versus CC-genotype, though
565 this was not replicated in the Global Lipid Genetic Consortium data(50).

There is some evidence that genetic variants affect response to drug treatment (for *PNPLA3*) but this is yet to be explored for *MBOAT7*. It will be equally interesting to assess whether somatic genotype of variants associated with HCC affects treatment response.

A strength of this analysis is the inclusion of data from individuals of multiple ethnicities (and genetic ancestries). We found no difference in the impact of the variant on liver disease among Caucasian and non-Caucasian individuals. Another strength is the large number of individuals with liver biopsy-derived phenotypic data.

Limitations and quality of evidence

An important practical consideration is the population frequency of this variant in different ethnicities. The mean allelic frequency of the effect (T-)allele is highly variable: from 0.24 in East Asians compared to 0.53 in those of South Asian ancestry.

Studies measured hepatic fat using several different imaging modalities, which have varying sensitivity for quantification of liver fat. This may have accounted for some of the heterogeneity observed in these analyses. There was a trend towards more positive associations in population-based studies using more sensitive techniques (MRI or MRS). It is possible that weighting towards large CT-based studies could have underestimated the true effect size.

We found significant differences between adult and paediatric histological analyses though a consistent trend was observed in the analysis of hepatic fat fraction. There are several potential reasons, including: sample size insufficient to demonstrate an effect, variations in imaging quantification of fat, too few clinical events (i.e. with fibrosis) to demonstrate an effect, different histology of paediatric NASH, or a true alternative effect of this variant on paediatric NAFLD.

Though there was minimal heterogeneity across included studies, the numbers of individuals with NAFLD and HCC were comparatively low. Further work in this area may improve the accuracy of effect estimates.

Conclusions

rs641738C>T near *MBOAT7* increases risk of NASH, fibrosis, and HCC in NAFLD with a small, positive effect on total liver fat and no impact on insulin resistance. These data validate this locus as significant in the pathogenesis of NAFLD.

ACKNOWLEDGEMENTS

The authors are grateful to the Raine Study participants and their families, and to the Raine Study research staff for cohort coordination and data collection. The authors gratefully acknowledge the following institutes for

616 providing funding for Core Management of the Raine Study: The University of
617 Western Australia (UWA), Curtin University, the Raine Medical Research
618 Foundation, the UWA Faculty of Medicine, Dentistry and Health Sciences, the
619 Telethon Kids Institute, the Women and Infants Research Foundation (King
620 Edward Memorial Hospital) and Edith Cowan University).
621 We are extremely grateful to all the families who took part in the ALSPAC
622 study, the midwives for their help in recruiting them, and the whole ALSPAC
623 team, which includes interviewers, computer and laboratory technicians,
624 clerical workers, research scientists, volunteers, managers, receptionists and
625 nurses.
626 This study has been conducting using data from the Fenland study. The
627 authors gratefully acknowledge the help of the MRC Epidemiology Unit
628 Support Teams, including Field, Laboratory and Data Management Teams.
629 The authors are grateful to the members of the EU-PNAFLD Registry,
630 including Anita Vreugdenhil, Anna Alisi, Piotr Socha, Wojciech Jańczyk, Ulrich
631 Baumann, Sanjay Rajwal, Indra van Mourik, Florence Lacaille, Myriam
632 Dabbas, Deirdre A. Kelly, Quentin M. Anstee and the late Valerio Nobili. We
633 would also like to thank Naga Chalasani for his helpful comments. This
634 research has made use of the UK Biobank resource under project number
635 9914.
636

637 **REFERENCES**

638 1. Speliotes EK, Yerges-armstrong LM, Wu J, Hernaez R, Lauren J,
639 Palmer CD, et al. Genome-Wide Association Analysis Identifies
640 Variants Associated with Nonalcoholic Fatty Liver Disease That Have
641 Distinct Effects on Metabolic Traits. Plos Genet. 2011;7:e1001324.
642 2. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and
643 NASH: Clinical impact. J. Hepatol. [Internet]. 2018;68:268–279.
644 Available from: https://doi.org/10.1016/j.jhep.2017.09.003
645 3. Buch S, Stickel F, Trépo E, Way M, Herrmann A, Nischalke HD, et al. A
646 genome-wide association study confirms PNPLA3 and identifies
647 TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat.
648 Genet. [Internet]. 2015;47:1443–1448. Available from:
649 http://dx.doi.org/10.1038/ng.3417
650 4. Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta
651 R, et al. The MBOAT7-TMC4 Variant rs641738 Increases Risk of
652 Nonalcoholic Fatty Liver Disease in Individuals of European Descent.
653 Gastroenterology. 2016;150:1219-1230e6.
654 5. Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, Miele L, et al.
655 MBOAT7 rs641738 variant and hepatocellular carcinoma in non-
656 cirrhotic individuals. Sci. Rep. [Internet]. 2017;7:4492. Available from:
657 http://www.nature.com/articles/s41598-017-04991-0
658 6. Gijón MA, Riekhof WR, Zarini S, Murphy RC, Voelker DR.
659 Lysophospholipid acyltransferases and arachidonate recycling in human
660 neutrophils. J. Biol. Chem. 2008;283:30235–30245.
661 7. Consortium TGte. The Genotype-Tissue Expression (GTEx) project.

662 Nat. Genet. 2013;45:580–585.
663 8. Luukkonen PK, Zhou Y, Hyötyläinen T, Leivonen M, Arola J, Orho-
664 Melander M, et al. The MBOAT7 variant rs641738 alters hepatic
665 phosphatidylinositols and increases severity of non-alcoholic fatty liver
666 disease in humans. J. Hepatol. [Internet]. 2016;65:1263–1265.
667 Available from:
668 http://www.sciencedirect.com/science/article/pii/S0168827816304214
669 9. Krawczyk M, Rau M, Schattenberg JM, Bantel H, Pathil A, Demir M, et
670 al. Combined effects of the *PNPLA3* rs738409, *TM6SF2* rs58542926,
671 and *MBOAT7* rs641738 variants on NAFLD severity: a multicenter
672 biopsy-based study. J. Lipid Res. [Internet]. 2017;58:247–255. Available
673 from: http://www.jlr.org/lookup/doi/10.1194/jlr.P067454
674 10. Koo BK, Joo SK, Kim D, Bae JM, Park JH, Kim JH, et al. Additive
675 effects of PNPLA3 and TM6SF2 on the histological severity of non-
676 alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2018;33:1277–
677 1285.
678 11. Sookoian S, Flichman D, Garaycoechea ME, Gazzi C, Martino JS,
679 Castaño GO, et al. Lack of evidence supporting a role of TMC4-
680 rs641738 missense variant - MBOAT7- intergenic downstream variant -
681 In the Susceptibility to Nonalcoholic Fatty Liver Disease. Sci. Rep.
682 2018;8:5097.
683 12. Umano GR, Caprio S, Di Sessa A, Chalasani N, Dykas DJ, Pierpont B,
684 et al. The rs626283 variant in the MBOAT7 gene is associated with
685 insulin resistance and fatty liver in Caucasian obese youth. Am. J.
686 Gastroenterol. [Internet]. 2018;113:376–383. Available from:

687 http://dx.doi.org/10.1038/ajg.2018.1
688 13. Hudert CA, Selinski S, Rudolph B, Bläker H, Christoph, Loddenkemper,
689 et al. Genetic determinants of steatosis and fibrosis progression in
690 pediatric non-alcoholic fatty liver disease. Liver Int. 2018;In Press:doi:
691 10.1111/liv.14006.
692 14. Johansen A, Rosti RO, Musaev D, Sticca E, Harripaul R, Zaki M, et al.
693 Mutations in MBOAT7, Encoding Lysophosphatidylinositol
694 Acyltransferase I, Lead to Intellectual Disability Accompanied by
695 Epilepsy and Autistic Features. Am. J. Hum. Genet. 2016;99:912–916.
696 15. Pelusi S, Baselli G, Pietrelli A, Dongiovanni P, Donati B, McCain MV, et
697 al. Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma
698 in Nonalcoholic Fatty Liver Disease. Sci. Rep. 2019;9:1–10.
699 16. Staley JR, Blackshaw J, Kamat MA, Ellis S, Surendran P, Sun BB, et al.
700 PhenoScanner: A database of human genotype-phenotype
701 associations. Bioinformatics. 2016;32:3207–3209.
702 17. Canela-Xandri O, Rawlik K, Tenesa A. An atlas of genetic associations
703 in UK Biobank. Nat. Genet. [Internet]. 2018;50:1593–1599. Available
704 from: http://www.ncbi.nlm.nih.gov/pubmed/30349118
705 18. De Lucia Rolfe E, Brage S, Sleigh A, Finucane F, Griffin SJ, Wareham
706 NJ, et al. Validity of ultrasonography to assess hepatic steatosis
707 compared to magnetic resonance spectroscopy as a criterion method in
708 older adults. PLoS One. 2018;13:87–99.
709 19. Dongiovanni P, Stender S, Pietrelli A, Mancina RM, Cespiati A, Petta S,
710 et al. Causal relationship of hepatic fat with liver damage and insulin
711 resistance in nonalcoholic fatty liver. J. Intern. Med. 2018;283:356–370.

712 20. Krawczyk M, Bantel H, Rau M, Schattenberg JM, Grünhage F, Pathil A,
713 et al. Could inherited predisposition drive non-obese fatty liver disease?
714 Results from German tertiary referral centers. J. Hum. Genet. [Internet].
715 2018;63:621–626. Available from: http://dx.doi.org/10.1038/s10038-018-
716 0420-4
717 21. DiStefano JK, Kingsley C, Craig Wood G, Chu X, Argyropoulos G, Still
718 CD, et al. Genome-wide analysis of hepatic lipid content in extreme
719 obesity. Acta Diabetol. 2014;52:373–382.
720 22. Adams LA, White SW, Marsh JA, Lye SJ, Connor KL, Maganga R, et al.
721 Association between liver-specific gene polymorphisms and their
722 expression levels with nonalcoholic fatty liver disease. Hepatology.
723 2013;57:590–600.
724 23. Stender S, Smagris E, Lauridsen BK, Kofoed KF, Nordestgaard BG,
725 Tybjærg-Hansen A, et al. Relationship between genetic variation at
726 PPP1R3B and levels of liver glycogen and triglyceride. Hepatology.
727 2018;67:2182–2195.
728 24. Mann JP, Pietzner M, Wittemans LB, Rolfe EDL, Kerrison N, Allison
729 ME, et al. Metabolomic patterns associated with known genetic variants
730 for hepatic steatosis and non-alcoholic steatohepatitisidentify
731 biomarkers that may be of utility in predicting adverse liver outcomes. J
732 Hepatol. 2018;68:S331–S332.
733 25. Kawaguchi T, Shima T, Mizuno M, Mitsumoto Y, Umemura A, Kanbara
734 Y, et al. Risk estimation model for nonalcoholic fatty liver disease in the
735 Japanese using multiple genetic markers. PLoS One. 2018;13:1–16.
736 26. Emdin CA, Haas M, Khera A V, Aragam K, Chaffin M, Jian L, et al. A

737 missense variant in Mitochondrial Amidoxime Reducing Component 1
738 gene and protection against liver disease. bioRxiv.
739 2019;http://dx.doi.org/10.1101/594523.
740 27. Guzman CB, Duvvuru S, Akkari A, Bhatnagar P, Battioui C, Foster W,
741 et al. Coding variants in PNPLA3 and TM6SF2 are risk factors for
742 hepatic steatosis and elevated serum alanine aminotransferases
743 caused by a glucagon receptor antagonist . Hepatol. Commun.
744 2018;2:561–570.
745 28. Wattacheril J, Lavine JE, Chalasani NP, Guo X, Kwon S, Schwimmer J,
746 et al. Genome-Wide Associations Related to Hepatic Histology in
747 Nonalcoholic Fatty Liver Disease in Hispanic Boys. J. Pediatr. [Internet].
748 2017;190:100-107.e2. Available from:
749 https://doi.org/10.1016/j.jpeds.2017.08.004
750 29. Chatterjee A, Das K, Singh P, Mondal D, Ghosh R, Chowdhury A, et al.
751 Exome-wide association study with hepatic fat content in nonalcoholic
752 fatty liver disease reveals significant association with 5 novel QTLs.
753 Hepatol. Int. 2018;12:181.
754 30. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, et al.
755 Cohort profile: The 'Children of the 90s'-The index offspring of the avon
756 longitudinal study of parents and children. Int. J. Epidemiol.
757 2013;42:111–127.
758 31. Northstone K, Lewcock M, Groom A, Boyd A, Macleod J, Timpson N, et
759 al. The Avon Longitudinal Study of Parents and Children (ALSPAC): an
760 updated on the enrolled sample of index children in 2019. Wellcome
761 Open Res. 2019;4:doi.org/10.12688/wellcomeopenres.15132.1.

762 32. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG.
763 Research electronic data capture (REDCap)-A metadata-driven
764 methodology and workflow process for providing translational research
765 informatics support. J. Biomed. Inform. 2009;42:377–381.
766 33. Martorell-Marugan J, Toro-Dominguez D, Alarcon-Riquelme ME,
767 Carmona-Saez P. MetaGenyo: A web tool for meta-analysis of genetic
768 association studies. BMC Bioinformatics. 2017;18:1–6.
769 34. Di Sessa A, Umano GR, Cirillo G, Del Prete A, Iacomino R, Marzuillo P,
770 et al. The Membrane-bound O-Acyltransferase7 rs641738 Variant in
771 Pediatric Nonalcoholic Fatty Liver Disease. J. Pediatr. Gastroenterol.
772 Nutr. 2018;67:69–74.
773 35. Di Costanzo A, Belardinilli F, Bailetti D, Sponziello M, D'Erasmo L,
774 Polimeni L, et al. Evaluation of Polygenic Determinants of Non-Alcoholic
775 Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing
776 Strategy. Sci. Rep. 2018;8:1–10.
777 36. Dongiovanni P, Meroni M, Mancina RM, Baselli G, Rametta R, Pelusi S,
778 et al. Protein phosphatase 1 regulatory subunit 3B gene variation
779 protects against hepatic fat accumulation and fibrosis in individuals at
780 high risk of nonalcoholic fatty liver disease. Hepatol. Commun.
781 2018;2:666–675.
782 37. Lin YC, Chang PF, Chang MH, Ni YH. Genetic determinants of hepatic
783 steatosis and serum cytokeratin-18 fragment levels in Taiwanese
784 children. Liver Int. 2018;38:1300–1307.
785 38. Viitasalo A, Eloranta A-M, Atalay M, Romeo S, Pihlajamaki J, Lakka TA.
786 Association of MBOAT7 gene variant with plasma ALT levels in

787 children: the PANIC study. Pediatr. Res. 2016;80:651–655.
788 39. Mann JP, Vreugdenhil A, Socha P, Jańczyk W, Baumann U, Rajwal S,
789 et al. European paediatric non-alcoholic fatty liver disease registry (EU-
790 PNAFLD): Design and rationale. Contemp. Clin. Trials. 2018;75:67–71.
791 40. Lauridsen BK, Stender S, Kristensen TS, Kofoed KF, Køber L,
792 Nordestgaard BG, et al. Liver fat content, non-alcoholic fatty liver
793 disease, and ischaemic heart disease: Mendelian randomization and
794 meta-analysis of 279 013 individuals. Eur. Heart J. 2018;39:385–393.
795 41. Luukkonen PK, Sädevirta S, Zhou Y, Kayser B, Ali A, Ahonen L, et al.
796 Saturated fat is more metabolically harmful for the human liver than
797 unsaturated fat or simple sugars. Diabetes Care. 2018;41:1732–1739.
798 42. Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, et
799 al. Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant
800 increases the risk to develop liver cirrhosis. Gut [Internet]. 2018;Epub
801 ahead:doi: 10.1136/gutjnl-2018-316228. Available from:
802 http://gut.bmj.com/lookup/doi/10.1136/gutjnl-2018-316228
803 43. von Schönfels W, Beckmann JH, Ahrens M, Hendricks A, Röcken C,
804 Szymczak S, et al. Histologic improvement of NAFLD in patients with
805 obesity after bariatric surgery based on standardized NAS (NAFLD
806 activity score). Surg. Obes. Relat. Dis. 2018;14:1607–1616.
807 44. Reichert M, Ripoll C, Casper M, Horn P, Bruns T, Grünhage F, et al.
808 Increased prevalence of low-frequency and rare NOD2 variants in
809 patients with liver cirrhosis. J. Hepatol. 2019;70:e442.
810 45. Abeysekera KW, Fernandes G, Hammerton G, Gordon F, Portal A,
811 Heron J, et al. The preavlence of non-alcoholic fatty liver disease in

812 young adults: An impending public health crisis? J. Hepatol.
813 2019;70:e45.
814 46. Schadt EE, Molony C, Chudin E, Hao K, Yang X, Lum PY, et al.
815 Mapping the genetic architecture of gene expression in human liver.
816 PLoS Biol. 2008;6:1020–1032.
817 47. Lee H-C, Inoue T, Sasaki J, Kubo T, Matsuda S, Nakasaki Y, et al.
818 LPIAT1 regulates arachidonic acid content in phosphatidylinositol and is
819 required for cortical lamination in mice. Mol. Biol. Cell. 2012;23:4689–
820 4700.
821 48. Shin S-Y, Fauman EB, Petersen A-K, Krumsiek J, Santos R, Huang J,
822 et al. An atlas of genetic influences on human blood metabolites. Nat
823 Genet [Internet]. 2014;46:543–550. Available from:
824 http://dx.doi.org/10.1038/ng.2982%5Cnhttp://www.nature.com/ng/journa
825 l/v46/n6/pdf/ng.2982.pdf
826 49. Helsley RN, Varadharajan V, Brown AL, Gromovsky AD, Schugar RC,
827 Ramachandiran I, et al. Obesity-linked suppression of membrane-
828 bound O -acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver
829 disease. Elife. 2019;8:e49882.
830 50. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni
831 S, et al. Discovery and refinement of loci associated with lipid levels.
832 Nat. Genet. 2013;45:1274–1285.
833